Skip to main content
NBTX
NASDAQ Life Sciences

Nanobiotix Finalizes $99.9M Global Offering to Fund Development Programs

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$41.01
Mkt Cap
$1.884B
52W Low
$3.64
52W High
$57.14
52W Position info
1027% above low
Off High info
28% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

NBTX has more than doubled off its 52-week low of $3.64.

Summary

Nanobiotix completed a $99.9 million global offering of ordinary shares and pre-funded warrants, securing significant capital to fund its development programs and extend its cash runway into early 2028.


Key Events · Financing and Capital Events · NBTX

  • Global Offering Finalized

    Nanobiotix finalized a global offering, raising approximately $99.9 million through the sale of 2,184,662 ordinary shares (including ADSs) and 345,099 pre-funded warrants, with an option for underwriters to purchase an additional 33,805 ADSs.

  • Pricing Details

    The ADSs were priced at $38.98, representing a ~5% discount to the current market price of $41.01. Each pre-funded warrant was priced at €33.57 (approximately $38.94) with an exercise price of €0.03.

  • Dilution and Capital Runway

    The offering is dilutive, potentially increasing outstanding shares by approximately 5.3%. The net proceeds of up to $93.8 million are expected to extend the company's cash runway into early 2028, supporting critical R&D.

  • Use of Proceeds

    Proceeds will be used to accelerate development programs, including JNJ-1900 (NBTXR3) and Nanoprimer platforms, and for general corporate purposes.


Analysis · NBTX · Life Sciences

This filing finalizes the terms and pricing of the global offering, previously announced on May 21, 2026. Nanobiotix successfully raised approximately $99.9 million through the sale of ordinary shares and pre-funded warrants. While dilutive for existing shareholders, this capital raise is crucial for the company, extending its cash runway into early 2028 and funding the acceleration of its JNJ-1900 (NBTXR3) and Nanoprimer development programs. The offering was priced at a modest discount to the current market price, indicating reasonable market demand, especially following recent positive clinical trial data.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NBTX was trading at $41.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $3.64 to $57.14. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NBTX - Latest Insights

NBTX
Oct 26, 2026, 6:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $30.26
Real-time Price: $26.90 info
Change: -$3.36 (-11%) info
Market Cap: $1.384B info
NBTX
Sep 24, 2026, 4:17 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $33.46
Real-time Price: $26.90 info
Change: -$6.56 (-20%) info
Market Cap: $1.384B info
NBTX
Sep 14, 2026, 6:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $38.00
Real-time Price: $26.90 info
Change: -$11.10 (-29%) info
Market Cap: $1.384B info
NBTX
Jun 02, 2026, 4:32 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $36.76
Real-time Price: $26.90 info
Change: -$9.86 (-27%) info
Market Cap: $1.384B info
NBTX
Jun 02, 2026, 4:30 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $36.76
Real-time Price: $26.90 info
Change: -$9.86 (-27%) info
Market Cap: $1.384B info